MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: Rationale for treatment of NF-κB-dependent lymphoma

Blood

Volumn 116, Issue 9, 2010, Pages 1515-1523

  Milhollen, Michael A ^a   Traore, Tary ^a   Adams Duffy, Jennifer ^a   Thomas, Michael P ^a   Berger, Allison J ^a   Dang, Lenny ^a   Dick, Lawrence R ^a   Garnsey, James J ^a   Koenig, Erik ^a   Langston, Steven P ^a   Manfredi, Mark ^a   Narayanan, Usha ^a   Rolfe, Mark ^a   Staudt, Louis M ^b   Soucy, Teresa A ^a   Yu, Jie ^a   Zhang, Julie ^a   Bolen, Joseph B ^a   Smith, Peter G ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; CYCLOPENTANE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NEDD8 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; UBIQUITIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; B LYMPHOCYTE; CELL CYCLE; CELL PROLIFERATION; DNA REPLICATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; GENETICS; GERMINAL CENTER; HUMAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CYCLOPENTANES; DNA REPLICATION; FEMALE; FLOW CYTOMETRY; GERMINAL CENTER; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, INBRED NOD; MICE, SCID; NF-KAPPA B; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UBIQUITINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956578834     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-272567     Document Type: Article

References (34)

1. Brownell JE, Sintchak MD, Gavin JM, et al. Substrate-assisted inhibition of ubiquitin-like protein activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell. 2010;37(1):102-111.
2. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res. 2009;15(12):3912-3916.
3. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458(7239):732-736.
4. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6(1):9-20. (Pubitemid 40064895)
5. Gong L, Yeh ET. Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. J Biol Chem. 1999;274(17):12036-12042. (Pubitemid 29197874)
6. Fujita M. Cdt1 revisited: complex and tight regulation during the cell cycle and consequences of deregulation in mammalian cells. Cell Div. 2006;1:22.
7. Vaziri C, Saxena S, Jeon Y, et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell. 2003;11(4):997-1008. (Pubitemid 36566321)
8. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301-310.
9. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell. 2004;13(6):853-865. (Pubitemid 38438480)
10. Ghosh S, Baltimore D. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature. 1990;344(6267):678-682. (Pubitemid 120028760)
11. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science. 1997;278(5339):860-866.
12. Read MA, Brownell JE, Gladysheva TB, et al. Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha. Mol Cell Biol. 2000;20(7):2326-2333.
13. Amir RE, Iwai K, Ciechanover A. The NEDD8 pathway is essential for SCF(beta -TrCP)-mediated ubiquitination and processing of the NF-kappa B precursor p105. J Biol Chem. 2002;277(26):23253-23259. (Pubitemid 34952153)
14. Fong A, Sun SC. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/ p100. J Biol Chem. 2002;277(25):22111-22114.
15. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
16. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861-1874. (Pubitemid 34028664)
17. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res. 2005;11(1):28-40.
18. Ngo VN, Davis RE, Lamy L, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006;441(7089):106-110.
19. Melixetian M, Ballabeni A, Masiero L, et al. Loss of Geminin induces rereplication in the presence of functional p53. J Cell Biol. 2004;165(4):473-482. (Pubitemid 38679613)
20. Ferch U, Kloo B, Gewies A, et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2009;206(11):2313-2320.
21. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
22. Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005;106(4):1392-1399.
23. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109(7):2700-2707.
24. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8(1):22-33.
25. Ni H, Ergin M, Huang Q, et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol. 2001;115(2):279-286.
26. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-721.
27. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009;459(7247):712-716.
28. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676-1679.
29. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.
30. Lam LT, Davis RE, Ngo VN, et al. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A. 2008;105(52):20798-20803.
31. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 1999;18(20):3063-3070. (Pubitemid 29261226)
32. Krappmann D, Emmerich F, Kordes U, et al. Molecular mechanisms of constitutive NF-kappaB/ Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18(4):943-953.
33. Barth TF, Martin-Subero JI, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101(9):3681-3686.
34. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5(4):297-309. (Pubitemid 40488635)